New hope for IBD patients: switching to guselkumab after ustekinumab fails
Disease control
Recruiting now
This Canadian study is testing whether switching to the drug guselkumab (Tremfya) can help people with inflammatory bowel disease (IBD) who didn't respond well enough to ustekinumab. Researchers will track symptoms, test results, and overall health in 200 participants over one ye…
Sponsor: TIDHI Innovation Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC